Video-Assisted Surgery Lung Cancer Survival

Video-Assisted Surgery Extends Survival for early-Stage Lung Cancer Patients

For individuals diagnosed with early-stage non-small cell lung cancer (NSCLC), video-assisted thoracic‍ surgery (VATS) is demonstrating a significant advantage over ‍traditional open surgery, leading to improved survival rates, according to research presented at the International Association for the Study of ⁤Lung Cancer (IASLC) 2024 World Conference on Lung Cancer, held September 9-12 in Singapore.

Study Details and findings

Researchers analyzed data from a large, international registry encompassing over 8,000 patients who underwent surgical resection for stage I NSCLC between January 2015 and December 2022. The study,⁢ published September 11, 2024, compared⁢ outcomes⁣ for ⁤those who had VATS lobectomy ⁣(removal of a‍ lung lobe) versus open lobectomy. ⁢

The analysis revealed that VATS lobectomy was associated with a 12% reduction in the risk of death compared to open surgery.Specifically,the five-year survival rate for ⁣patients undergoing VATS was 93.4% compared to 88.2% for those undergoing ‍open surgery. This difference was statistically significant,⁣ indicating it wasn’t due to chance.

Dr. Hiroshi Igami, lead author of the study and a thoracic surgeon at Kyoto University Hospital‍ in Japan, ⁤noted that the benefits of VATS were consistent across various‍ patient subgroups, including those with different tumor sizes and lymph node involvement. IASLC News Release

Why VATS Offers an Advantage

VATS involves making smaller incisions and using a camera and specialized instruments to⁤ perform the surgery. This minimally invasive approach offers several⁤ potential benefits:

• Reduced Trauma: Smaller incisions lead to less tissue damage and⁣ pain.
• Faster⁢ Recovery: Patients typically experience a shorter hospital stay and quicker return to‍ normal activities.
• Lower Complication Rates: VATS is generally associated with fewer post-operative complications, such as infections and bleeding.

While VATS has been increasingly adopted, some surgeons remain hesitant to use it for more complex cases.However, this study suggests that VATS can be safely and effectively used for a wider range of patients with early-stage lung cancer.

Implications for Patients and Future Research

the findings ‍reinforce the growing body of ⁢evidence supporting VATS as ‍the preferred surgical‍ approach for early-stage NSCLC when feasible.Patients diagnosed with stage I lung cancer should discuss the potential benefits and risks of both VATS and open surgery with their thoracic surgeon to determine the most appropriate treatment plan.

Researchers emphasize the need for continued research to identify factors that⁢ predict which patients ⁢will benefit most from VATS and to optimize⁣ surgical techniques⁤ to further improve outcomes. Future studies ⁣may also explore the role of VATS in combination with other therapies, such as chemotherapy and immunotherapy.